Stock 601607 SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Pharmaceuticals Holding Co., Ltd

Equities

601607

CNE000000C82

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
19.17 CNY +0.63% Intraday chart for Shanghai Pharmaceuticals Holding Co., Ltd -0.57% +14.58%
Jul. 04 Shanghai Pharmaceuticals Gets Nod to Register Ezetimibe Tablets MT
Jun. 28 Shanghai Pharmaceuticals Holding Co., Ltd Announces Final Dividend for the Year Ended 31 December 2023, Payable on 27 August 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 47,781 47,493 49,277 60,072 56,107 63,214 - -
Enterprise Value (EV) 1 63,090 55,488 57,141 69,931 69,900 73,595 74,811 73,498
P/E ratio 12.8 x 12.2 x 11.1 x 11.1 x 16.4 x 14 x 12.3 x 10.8 x
Yield 2.4% 2.5% 2.11% 3.42% 2.45% 2.81% 3.18% 3.68%
Capitalization / Revenue 0.26 x 0.25 x 0.23 x 0.26 x 0.22 x 0.22 x 0.2 x 0.18 x
EV / Revenue 0.34 x 0.29 x 0.26 x 0.3 x 0.27 x 0.26 x 0.24 x 0.21 x
EV / EBITDA 8.22 x 5.85 x 5.53 x 6.24 x 6.27 x 6.16 x 5.8 x 5.23 x
EV / FCF 19.3 x 13.2 x 60.6 x 31.5 x 28.6 x 35.1 x 115 x 21.4 x
FCF Yield 5.18% 7.6% 1.65% 3.17% 3.49% 2.85% 0.87% 4.68%
Price to Book 1.25 x 1.2 x 1.14 x 0.98 x 0.9 x 0.98 x 0.93 x 0.88 x
Nbr of stocks (in thousands) 2,842,089 2,842,089 2,842,089 3,696,414 3,703,301 3,703,523 - -
Reference price 2 18.37 19.20 19.87 17.83 16.73 19.17 19.17 19.17
Announcement Date 3/27/20 3/26/21 3/29/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 186,566 191,909 215,824 231,981 260,295 287,915 317,386 346,952
EBITDA 1 7,672 9,483 10,324 11,216 11,151 11,940 12,900 14,054
EBIT 1 6,214 7,184 8,205 9,015 7,667 10,020 11,335 12,556
Operating Margin 3.33% 3.74% 3.8% 3.89% 2.95% 3.48% 3.57% 3.62%
Earnings before Tax (EBT) 1 6,262 7,175 8,144 8,808 7,054 8,444 9,742 11,062
Net income 1 4,081 4,496 5,093 5,617 3,768 4,967 5,599 6,302
Net margin 2.19% 2.34% 2.36% 2.42% 1.45% 1.73% 1.76% 1.82%
EPS 2 1.440 1.580 1.790 1.610 1.020 1.370 1.553 1.777
Free Cash Flow 1 3,269 4,219 942.6 2,219 2,440 2,099 650.1 3,442
FCF margin 1.75% 2.2% 0.44% 0.96% 0.94% 0.73% 0.2% 0.99%
FCF Conversion (EBITDA) 42.61% 44.49% 9.13% 19.78% 21.88% 17.58% 5.04% 24.49%
FCF Conversion (Net income) 80.11% 93.83% 18.51% 39.5% 64.76% 42.25% 11.61% 54.62%
Dividend per Share 2 0.4400 0.4800 0.4200 0.6100 0.4100 0.5390 0.6095 0.7064
Announcement Date 3/27/20 3/26/21 3/29/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 54,852 - 54,809 62,904 57,369 66,226 66,366 64,916 62,787 70,153 73,798 73,798 70,525 78,627 80,537
EBITDA 1 - - - - - - - - - - 3,168 2,720 2,010 3,360 3,471
EBIT 1 1,404 - 3,804 1,822 1,393 2,666 1,893 1,998 1,489 2,415 2,742 2,295 1,584 2,909 3,020
Operating Margin 2.56% - 6.94% 2.9% 2.43% 4.02% 2.85% 3.08% 2.37% 3.44% 3.72% 3.11% 2.25% 3.7% 3.75%
Earnings before Tax (EBT) 1 - - - - - - - - - 2,417 2,352 2,359 1,478 2,585 2,689
Net income 1 - - - - - - - - - 1,542 1,538 1,298 690.6 1,699 1,686
Net margin - - - - - - - - - 2.2% 2.08% 1.76% 0.98% 2.16% 2.09%
EPS 2 0.2100 0.4400 0.6900 0.3000 0.1600 0.4100 0.3000 0.3200 -0.0100 0.4200 0.3727 0.3303 0.2682 0.3994 0.4377
Dividend per Share 2 - - - - - - - - - - 0.5516 - - - 0.6061
Announcement Date 3/29/22 4/28/22 8/29/22 10/27/22 3/30/23 4/26/23 8/29/23 10/27/23 3/28/24 4/26/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,309 528 7,864 9,858 13,792 13,267 11,597 10,283
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.995 x 0.0568 x 0.7617 x 0.879 x 1.237 x 1.111 x 0.899 x 0.7317 x
Free Cash Flow 1 3,269 3,835 943 2,219 2,440 2,099 650 3,442
ROE (net income / shareholders' equity) 10.1% 10.3% 10.8% 9.11% 5.56% 7.13% 7.82% 8.31%
ROA (Net income/ Total Assets) 3.09% 3.14% 3.26% 3.11% 1.84% 2.66% 2.78% 3.05%
Assets 1 131,943 143,105 156,308 180,784 205,005 186,807 201,413 206,273
Book Value Per Share 2 14.70 16.00 17.40 18.10 18.50 19.50 20.50 21.90
Cash Flow per Share 2 2.120 2.410 1.780 1.280 1.410 1.810 1.810 1.830
Capex 1 2,753 3,010 4,119 2,525 2,791 2,734 3,021 3,113
Capex / Sales 1.48% 1.57% 1.91% 1.09% 1.07% 0.95% 0.95% 0.9%
Announcement Date 3/27/20 3/26/21 3/29/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shanghai Pharmaceuticals Holding Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
19.17 CNY
Average target price
20.67 CNY
Spread / Average Target
+7.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+14.58% 8.69B
MCKESSON CORPORATION Stock McKesson Corporation
+26.75% 76.12B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
-3.96% 7.91B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-35.36% 6.45B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+25.52% 5.75B
GALENICA AG Stock Galenica AG
+2.96% 4.16B
EBOS GROUP LIMITED Stock EBOS Group Limited
-7.24% 3.89B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
-12.59% 3.21B
MEDIPAL HOLDINGS CORPORATION Stock MediPal Holdings Corporation
+12.84% 3.25B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+6.85% 3.17B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 601607 Stock
  4. Financials Shanghai Pharmaceuticals Holding Co., Ltd